HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Industry Outreach To State Officials Pays Off – Former Maryland AG

This article was originally published in The Rose Sheet

Executive Summary

State attorneys general largely are discriminating good from bad supplement industry actors, says former Maryland AG Doug Gansler following the annual meeting of the Western Attorneys General. State officials' brighter take on supplement firms stems from industry outreach and education efforts.

You may also be interested in...



States' Scrutiny Of Supplement Industry Could Climb Following Mid-Terms

“If this regulatory rollback in Washington continues I think we could see over the next few years AGs start to say, ‘Oh the FTC is not doing what it necessarily should be doing, or 'the FDA is not doing enough,' so these AGs could take over in that space,” says Lori Kalani, co-chair of law firm Cozen O’Connor’s state attorneys general practice. That could happen particularly if Democrats win more AG offices in mid-term elections.

Walmart Cuts Verification Claim: Health And Wellness Industry Roundup

Sacco joins Prestige Brands as CFO another spiked supplement in international mali; and BIGR gains $55m funding.

GNC Shares GMP Guidelines To Boost Compliance, Not Suggest DSHEA Reform

Sharing the guidelines across the industry should help firms comply with FDA's GMPs required under dietary supplement statutes, says GNC CEO Mike Archbold.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel